Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

This bill extends federal funding for sickle cell disease and related blood disorder programs. It reauthorizes existing research, surveillance, prevention, and treatment activities under the Public Health Service Act through 2028, replacing the previous 2024-2028 funding period. The primary effect is ensuring continued support for NIH and CDC programs focused on these conditions. It does not create new programs or change existing services - only extends current funding authorization.